JP MORGAN/CALL/VERTEX PHARMACEUTICALS/370/0.1/21.06.24 | Market Closed - Börse Stuttgart 02:40:10 2024-06-14 EDT | ||
| 10.2 EUR | +3.87% |
|
| Current month | +48.47% | ||
| 1 month | +74.66% |
Comparison chart between the derivative product and it's underlying value
End-of-day quotes
Latest news about VERTEX PHARMACEUTICALS INCORPORATED
More news
| Date | Price | Change |
|---|---|---|
| 24-06-14 | 10.2 | +3.87% |
| 24-06-13 | 9.82 | -7.53% |
| 24-06-12 | 10.62 | +0.28% |
| 24-06-11 | 10.59 | +0.09% |
| 24-06-10 | 10.58 | -1.21% |
Delayed Quote Börse Stuttgart
Last update June 14, 2024 at 02:40 am
More quotesStatic data
| Product type | Plain-Vanilla-Warrants |
|---|---|
| Buy / Sell | CALL |
| Underlying | VERTEX PHARMACEUTICALS INCORPORATED |
| Issuer | J.P. Morgan |
| WKN | JL06S5 |
| ISIN | DE000JL06S59 |
| Date issued | 2023-03-28 |
| Strike | 370 $ |
| Maturity | 2024-06-21 (6 Days) |
| Parity | 10 : 1 |
| Emission price | 2.73 € |
| Emission volume | N/A |
| Settlement | cash |
| Currency | EUR |
Technical Indicators
| Highest since issue | 10.71 € |
|---|---|
| Lowest since issue | 2.54 € |
Company Profile
Vertex Pharmaceuticals Incorporated specializes in the research, development and marketing of micromolecular drugs primarily for the treatment of cancers, viral, inflammatory and auto-immune diseases.
Net sales are distributed geographically as follows: the United States (61.2%), Europe (31.5%) and other (7.3%).
Sector
-
Ratings for Vertex Pharmaceuticals Incorporated
Trading Rating
Investor Rating
ESG Refinitiv
B+
Consensus: Vertex Pharmaceuticals Incorporated
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
31
Last Close Price
480.7
USD
Average target price
463.4
USD
Spread / Average Target
-3.60%
- Stock Market
- Warrants
- Warrant
